Free Trial Information
BioCentury | Nov 28, 2018
Company News

Management tracks: Abeona, INKEF, Incyte

...ProFibrix B.V., which The Medicines Co. (NASDAQ:MDCO) acquired in 2013, and fibrosis and cardiovascular company Lanthio Pharma B.V....
Read More
BioCentury | Nov 6, 2018
Company News

Management tracks: Audentes, Veloxis

...hired Axel Mescheder as CEO and CMO. Mescheder was CMO and chief development officer at Lanthio Pharma B.V....
Read More
BioCentury | Jun 9, 2017
Company News

Management tracks

...CEO. Cancer company ViraTherapeutics GmbH (Innsbruck, Austria) named Heinz Schwer CEO. He was CEO of Lanthio Pharma B.V....
Read More
BioCentury | Feb 22, 2017
Clinical News

MOR107: Ph I started

...MorphoSys said its Lanthio Pharma B.V. subsidiary began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate single...
Read More
BioCentury | Sep 23, 2016
Company News

Management tracks

...successor in both roles. Campanelli was president of Endo's Par Pharmaceutical Holdings Inc. subsidiary. The Lanthio Pharma B.V....
Read More
BioCentury | Sep 19, 2016
Finance

Expanding INKEF

...Xetra:MOR; Pink:MPSYF) paid €20 million ($22.3 million) for the 80% of fibrosis and cardiovascular company Lanthio Pharma B.V....
Read More
BioCentury | May 11, 2015
Company News

Lanthio Pharma, MorphoSys deal

...in November 2012 as part of a series A round (see BioCentury, Dec. 3, 2012). Lanthio Pharma B.V....
Read More
BioCentury | May 8, 2015
Company News

MorphoSys acquires Lanthio

...Xetra:MOR; Pink:MPSYF) said it will acquire all the shares it does not already own of Lanthio Pharma B.V....
Read More
BioCentury | Nov 24, 2014
Company News

Lanthio Pharma, MorphoSys deal

...or subcutaneous delivery. MorphoSys said financial terms are not disclosed (see BioCentury, Dec. 3, 2012). Lanthio Pharma B.V....
Read More
BioCentury | Jun 2, 2014
Financial News

Lanthio Pharma completes venture financing

Lanthio Pharma B.V. , Groningen, the Netherlands Business: Pulmonary, Cardiovascular, Autoimmune Date completed: 5/21/14 Type: Venture financing Raised: €1.4 million ($2 million) Investors: Netherlands Enterprise Agency; existing investors Note: The amount raised includes €720,000 ($984,816) of...
Read More
Items per page:
1 - 10 of 19
BioCentury | Nov 28, 2018
Company News

Management tracks: Abeona, INKEF, Incyte

...ProFibrix B.V., which The Medicines Co. (NASDAQ:MDCO) acquired in 2013, and fibrosis and cardiovascular company Lanthio Pharma B.V....
Read More
BioCentury | Nov 6, 2018
Company News

Management tracks: Audentes, Veloxis

...hired Axel Mescheder as CEO and CMO. Mescheder was CMO and chief development officer at Lanthio Pharma B.V....
Read More
BioCentury | Jun 9, 2017
Company News

Management tracks

...CEO. Cancer company ViraTherapeutics GmbH (Innsbruck, Austria) named Heinz Schwer CEO. He was CEO of Lanthio Pharma B.V....
Read More
BioCentury | Feb 22, 2017
Clinical News

MOR107: Ph I started

...MorphoSys said its Lanthio Pharma B.V. subsidiary began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate single...
Read More
BioCentury | Sep 23, 2016
Company News

Management tracks

...successor in both roles. Campanelli was president of Endo's Par Pharmaceutical Holdings Inc. subsidiary. The Lanthio Pharma B.V....
Read More
BioCentury | Sep 19, 2016
Finance

Expanding INKEF

...Xetra:MOR; Pink:MPSYF) paid €20 million ($22.3 million) for the 80% of fibrosis and cardiovascular company Lanthio Pharma B.V....
Read More
BioCentury | May 11, 2015
Company News

Lanthio Pharma, MorphoSys deal

...in November 2012 as part of a series A round (see BioCentury, Dec. 3, 2012). Lanthio Pharma B.V....
Read More
BioCentury | May 8, 2015
Company News

MorphoSys acquires Lanthio

...Xetra:MOR; Pink:MPSYF) said it will acquire all the shares it does not already own of Lanthio Pharma B.V....
Read More
BioCentury | Nov 24, 2014
Company News

Lanthio Pharma, MorphoSys deal

...or subcutaneous delivery. MorphoSys said financial terms are not disclosed (see BioCentury, Dec. 3, 2012). Lanthio Pharma B.V....
Read More
BioCentury | Jun 2, 2014
Financial News

Lanthio Pharma completes venture financing

Lanthio Pharma B.V. , Groningen, the Netherlands Business: Pulmonary, Cardiovascular, Autoimmune Date completed: 5/21/14 Type: Venture financing Raised: €1.4 million ($2 million) Investors: Netherlands Enterprise Agency; existing investors Note: The amount raised includes €720,000 ($984,816) of...
Read More
Items per page:
1 - 10 of 19